GS
IOVA icon

GTS Securities’s Iovance Biotherapeutics IOVA Stock Holding History

GTS Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28,800
Closed -$131K – 4207
2023
Q3 		$131K Buy
+28,800
New +$188K ﹤0.01% 3547

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

GTS Securities's IOVA Position: Q1 2026 in Review

GTS Securities opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 10,004 shares worth $35.1K. The stake represents ﹤0.01% of the portfolio and ranks #1444 among its holdings. This is a return to the name: GTS Securities previously reported a position in IOVA as recently as Q1 2024.

GTS Securities first reported a position in IOVA in Q2 2023 and has held it in 5 quarters since. The position peaked at $542K in Q4 2023. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • GTS Securities held 10,004 shares of Iovance Biotherapeutics worth $35.1K as of Q1 2026.
  • Iovance Biotherapeutics was a new GTS Securities position in Q1 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1444 holding.
  • GTS Securities first reported a position in Iovance Biotherapeutics in Q2 2023 and has held it in 5 quarters since.
  • GTS Securities's Iovance Biotherapeutics position peaked at $542K in Q4 2023.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.